This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
19 Oct 2010

Reshape NICE Remit to Fit New ‘Value’ Era, Says ABPI

The Association of the British Pharmaceutical Industry (ABPI) has called for a change in the remit of NICE, to equip it for the future 'value-based' era envisaged by Government.

The Association of the British Pharmaceutical Industry (ABPI) has called for a change in the remit of NICE, to equip it for the future ‘value-based’ era envisaged by Government. Speaking (on 19 October 2010) at the Westminster Health Forum, which is holding a seminar on the changing role of NICE, Dr Richard Barker, Director General of the ABPI, sets out a three-point plan for the future:
• Broaden NICE’s definition of value to capture all the key elements of healthcare innovation, and reflect uncertainties in early assessment of medicines in value ranges.
• Refocus attention on clinical best practice and quality standards and how innovation can advance both.
• Dismantle NHS processes that ‘second-guess’ NICE conclusions.

“As debate begins on the design of a future ‘value-based’ approach to how the NHS pays for medicines, it’s vital we have a parallel debate on the role and focus of NICE.”

Related News